Godsey & Gibb Inc. Boosts Stock Position in Amgen Inc. $AMGN

Godsey & Gibb Inc. lifted its position in Amgen Inc. (NASDAQ:AMGN) by 9.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,568 shares of the medical research company’s stock after acquiring an additional 6,565 shares during the quarter. Godsey & Gibb Inc.’s holdings in Amgen were worth $20,262,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Joel Isaacson & Co. LLC increased its holdings in shares of Amgen by 2.5% in the second quarter. Joel Isaacson & Co. LLC now owns 6,198 shares of the medical research company’s stock valued at $1,731,000 after purchasing an additional 149 shares during the period. Tyche Wealth Partners LLC boosted its holdings in Amgen by 4.5% in the 2nd quarter. Tyche Wealth Partners LLC now owns 1,484 shares of the medical research company’s stock worth $414,000 after buying an additional 64 shares during the last quarter. KLP Kapitalforvaltning AS lifted its holdings in Amgen by 4.6% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 192,216 shares of the medical research company’s stock valued at $53,669,000 after purchasing an additional 8,500 shares in the last quarter. RMG Wealth Management LLC purchased a new position in Amgen in the 2nd quarter worth approximately $152,000. Finally, SteelPeak Wealth LLC raised its stake in Amgen by 367.9% during the second quarter. SteelPeak Wealth LLC now owns 143,292 shares of the medical research company’s stock worth $40,008,000 after purchasing an additional 112,669 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Down 1.3%

AMGN stock opened at $294.12 on Tuesday. The firm has a 50 day simple moving average of $287.20 and a 200 day simple moving average of $287.83. The firm has a market cap of $158.34 billion, a PE ratio of 24.05, a P/E/G ratio of 2.59 and a beta of 0.49. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $335.88.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, beating analysts’ consensus estimates of $5.28 by $0.74. The firm had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date was Friday, August 22nd. Amgen’s dividend payout ratio (DPR) is presently 77.84%.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the transaction, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.69% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Friday. Raymond James Financial began coverage on shares of Amgen in a research note on Wednesday, September 3rd. They set a “market perform” rating for the company. Morgan Stanley increased their target price on Amgen from $330.00 to $333.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Weiss Ratings restated a “hold (c+)” rating on shares of Amgen in a report on Saturday, September 27th. Finally, UBS Group decreased their price objective on Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 6th. Seven investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus price target of $309.42.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.